Cronos Group (CRON) Competitors $2.62 +0.07 (+2.75%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$2.62 +0.00 (+0.19%) As of 10/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRON vs. ACB, CGC, OGI, SNDL, TLRY, PCVX, ACLX, KYMR, CRNX, and PTGXShould you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Aurora Cannabis (ACB), Canopy Growth (CGC), Organigram Global (OGI), SNDL (SNDL), Tilray Brands (TLRY), Vaxcyte (PCVX), Arcellx (ACLX), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Cronos Group vs. Its Competitors Aurora Cannabis Canopy Growth Organigram Global SNDL Tilray Brands Vaxcyte Arcellx Kymera Therapeutics Crinetics Pharmaceuticals Protagonist Therapeutics Cronos Group (NASDAQ:CRON) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Do institutionals & insiders believe in CRON or ACB? 8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 6.9% of Cronos Group shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer CRON or ACB? In the previous week, Aurora Cannabis had 2 more articles in the media than Cronos Group. MarketBeat recorded 2 mentions for Aurora Cannabis and 0 mentions for Cronos Group. Aurora Cannabis' average media sentiment score of 1.28 beat Cronos Group's score of 0.23 indicating that Aurora Cannabis is being referred to more favorably in the news media. Company Overall Sentiment Cronos Group Neutral Aurora Cannabis Positive Which has higher valuation and earnings, CRON or ACB? Cronos Group has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$117.61M8.53$41.08M$0.0552.40Aurora Cannabis$246.72M1.41$1.63M-$0.19-32.47 Is CRON or ACB more profitable? Cronos Group has a net margin of 14.19% compared to Aurora Cannabis' net margin of -5.66%. Aurora Cannabis' return on equity of -1.49% beat Cronos Group's return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group14.19% -3.78% -3.62% Aurora Cannabis -5.66%-1.49%-1.06% Which has more volatility and risk, CRON or ACB? Cronos Group has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Do analysts prefer CRON or ACB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Aurora Cannabis 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.60 SummaryAurora Cannabis beats Cronos Group on 10 of the 16 factors compared between the two stocks. Get Cronos Group News Delivered to You Automatically Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRON vs. The Competition Export to ExcelMetricCronos GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$976.38M$2.66B$6.12B$10.65BDividend YieldN/A56.92%5.69%4.74%P/E Ratio52.4023.8685.6126.85Price / Sales8.53745.61612.81135.13Price / Cash5,480.10169.9037.7861.77Price / Book0.905.5913.256.70Net Income$41.08M$32.78M$3.30B$276.44M7 Day Performance-1.50%4.01%3.87%2.48%1 Month Performance5.65%10.63%8.33%8.79%1 Year Performance20.74%-1.80%88.97%34.41% Cronos Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRONCronos Group1.4634 of 5 stars$2.62+2.7%N/A+19.1%$976.38M$117.61M52.40450ACBAurora Cannabis0.4966 of 5 stars$6.23+28.2%N/A+15.3%$350.25M$246.72M-32.791,130Positive NewsHigh Trading VolumeCGCCanopy Growth0.6074 of 5 stars$1.57+17.2%N/A-65.5%$376.56M$225.65M-0.523,150High Trading VolumeOGIOrganigram Global0.7138 of 5 stars$1.97+16.6%N/A+14.0%$264.65M$117.47M39.41860High Trading VolumeSNDLSNDL3.1212 of 5 stars$2.74+17.6%$4.50+64.2%+35.2%$720.02M$671.81M-10.152,516Analyst DowngradeHigh Trading VolumeTLRYTilray Brands2.1048 of 5 stars$1.85+60.9%$1.94+4.7%+3.6%$2.04B$821.31M-0.802,842Upcoming EarningsHigh Trading VolumePCVXVaxcyte2.4346 of 5 stars$34.65+2.0%$106.25+206.6%-61.4%$4.50BN/A-8.43160ACLXArcellx2.2237 of 5 stars$79.11-0.8%$114.31+44.5%+12.0%$4.39B$107.94M-23.1380KYMRKymera Therapeutics2.0379 of 5 stars$58.50+4.0%$59.95+2.5%+34.8%$4.18B$47.07M-16.86170CRNXCrinetics Pharmaceuticals3.8766 of 5 stars$43.51-5.2%$73.20+68.2%-17.9%$4.10B$1.04M-10.59210High Trading VolumePTGXProtagonist Therapeutics2.1052 of 5 stars$65.14-3.4%$68.36+4.9%+49.5%$4.05B$434.43M93.06120Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies ACB Alternatives CGC Alternatives OGI Alternatives SNDL Alternatives TLRY Alternatives PCVX Alternatives ACLX Alternatives KYMR Alternatives CRNX Alternatives PTGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRON) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cronos Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cronos Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
